Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
After a solid process, which was delayed by the pandemic, ChemoTech has now reached a long-awaited milestone by establishing a Centre of Excellence "CoE" at the India Sweden Healthcare Innovation Centre. This Innovation Centre is physically located at the All India Institute of Medical Sciences (AIIMS) Jodhpur and is part of the state cooperation in health care between Sweden and India and is an initiative that is co-financed by the Swedish and Indian states.
This agreement means that AIIMS Jodhpur and ChemoTech, through this CoE, will conduct clinical studies with the aim of creating clinical data and evidence for the effect of TSE treatment on various cancers. The first studies are planned to start during Q2-Q3 2022 and mainly include head andneck cancer, which accounts for approx. 30-40% [1.2] of all cancer cases in India (total number of cancer cases amounts to about 1.4 million cases[3]).
It is of great importance to ChemoTech that AIIMS now chooses to collaborate through the India-Sweden Healthcare Innovation Centre and thereby ensures access to ChemoTech `s technology and the opportunity to gather knowledge in order to build a CoE. ChemoTech will contribute with two IQwave systems. One system shall be dedicated to clinical studies and one for the training of future doctors in medical education, which constitutes an essential part of the institute's activities.
"We are very grateful for the help we have received through the government initiatives; The Embassy of Sweden in Delhi, and Business Sweden who run the Innovation Centre; also Swecare and the Sweden India Business Council have all contributed to this process. For the company, this is a very big step forward, which indicates that the general healthcare system in India also understands the unique opportunities that TSE can contribute to cancer care in India." - says Mohan Frick, CEO of ChemoTech
[1] Manik Rao Kulkarni, IJHNS, 2013;4(1):29-35
[2 ]Bhattacharjee A et al., IJOHNS 2006;58:15-19
[3 ]Mathur P et al., JCO Glob Oncol, 2020;6:1063-1075
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-11-2021 11:30 CET.